Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 1/20 | 0.36 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23139009 | 0.81 | KCNH2 (0.37) | KCNH2KDM4E | |
| SCHEMBL21783963 | 0.75 | — | — | |
| SCHEMBL24185368 | 0.70 | P2RX7 (0.33) | KDM4ELMNAP2RX7 | |
| SCHEMBL21158056 | 0.67 | CYP19A1 (0.41) | CYP17A1CYP1A2 | |
| SCHEMBL6521463 | 0.67 | FDPS (0.54) | KCNH2LMNA | |
| SCHEMBL18256662 | 0.67 | FDPS (0.54) | CYP17A1CYP1A2 | |
| SCHEMBL23064347 | 0.66 | MAP4K1 (0.37) | P2RX7 | |
| SCHEMBL21303136 | 0.65 | MEN1 (0.45) | KCNH2CYP1A2KDM4ELMNA | |
| SCHEMBL5983558 | 0.65 | — | — | |
| SCHEMBL21324097 | 0.65 | HTR2C (0.37) | KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024020034-A1 | CBL-B INHIBITORS AND METHODS OF USE THEREOF | ARCUS BIOSCIENCES, INC. (US) | 2024-01-25 | — | — | WO | disclosed |
| EP-3572401-B1 | ASK1 INHIBITOR AND PREPARATION METHOD AND USE THEREOF | FUJIAN COSUNTER PHARMACEUTICAL CO LTD (CN) | 2021-09-29 | — | — | EP | disclosed |
| US-10787435-B2 | ASK1 inhibitor and preparation method and use thereof | Fuijan Cosunter Pharmaceutical Co. Ltd. (CN) | 2020-09-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10787435-B2 | ASK1 inhibitor and preparation method and use thereof | MARK1, MAP3K1, MAP3K20 | KCNH2 4629/4885CYP17A1 527/4885CYP1A2 3503/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.